FairWinds Bio

FairWinds Bio is a Philadelphia-based biotechnology company dedicated to advancing the field of gene therapy through the development of next-generation viral vectors. Founded by industry veterans Stephen Squinto and Katherine High, who were instrumental in the success of Spark Therapeutics, the company focuses on engineering adeno-associated virus (AAV) capsids with improved tissue tropism and reduced immunogenicity. FairWinds Bio's proprietary platform aims to expand the reach of genetic medicines to a broader range of diseases, including those affecting the central nervous system and other complex organs. The company is currently in the pre-clinical stage and is supported by significant investment from Deerfield Management. By addressing the fundamental challenges of gene delivery and manufacturing, FairWinds Bio seeks to provide transformative treatments for patients with rare and debilitating genetic conditions.